Țară: Canada
Limbă: engleză
Sursă: Health Canada
ZOLMITRIPTAN
PRO DOC LIMITEE
N02CC03
ZOLMITRIPTAN
2.5MG
TABLET
ZOLMITRIPTAN 2.5MG
ORAL
6/30
Prescription
SELECTIVE SEROTONIN AGONISTS
Active ingredient group (AIG) number: 0134381001; AHFS:
CANCELLED POST MARKET
2021-04-07
PRODUCT MONOGRAPH PR ZOLMITRIPTAN Zolmitriptan Film-Coated Tablets, House Standard 2.5 mg PR ZOLMITRIPTAN ODT Zolmitriptan Orally Dispersible Tablets, House Standard 2.5 mg 5-HT1 RECEPTOR AGONIST MIGRAINE THERAPY DATE OF REVISION: MARCH 4, 2021 PRO DOC LTÉE 2925, boul. Industriel Laval, Québec H7L 3W9 Submission Control No.: 248801 Zolmitriptan Zolmitriptan PM-E.pdf Pg. 1 _ _ _ZOLMITRIPTAN and ZOLMITRIPTAN ODT Product Monograph _ _Page 2 of 41 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ...................................................... 3 SUMMARY PRODUCT INFORMATION ..................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................... 3 CONTRAINDICATIONS ............................................................................................... 4 WARNINGS AND PRECAUTIONS .............................................................................. 5 ADVERSE REACTIONS ............................................................................................ 12 DRUG INTERACTIONS .............................................................................................. 18 DOSAGE AND ADMINISTRATION ........................................................................... 20 OVERDOSAGE ............................................................................................................ 21 ACTION AND CLINICAL PHARMACOLOGY .......................................................... 22 STORAGE AND STABILITY ...................................................................................... 25 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................... 25 PART II: SCIENTIFIC INFORMATION ............................................................................ 26 PHARMACEUTICAL INFORMATION....................................................................... 26 CLINICAL TRIALS........................................................................ Citiți documentul complet